💊 Sotac Pharma: Profits Are Growing… But So Is Debtor Tension
Date of Publishing -
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
📈 At a Glance
Sotac Pharmaceuticals Ltd is a small-cap pharma manufacturer doing ₹97 Cr in annual sales and ₹8 Cr profit. Its FY25 OPM shot up to 14%, ROE hit 16%, and profit jumped 121%. But with debtor days rising to 128 and cash flows turning negative, this SME pharma play is not as clean as its antibiotics suggest.
🚨 1. Introduction with Hook
“Small cap pharma stock with 7x EPS growth” sounds like the beginning of a multibagger story… until you open the balance sheet.
Sotac Pharma has the numbers — profit up 121%, margins doubled, ROE/ROCE rising. But like every good SME plot twist, the cash is missing, and the working capital cycle looks like a tangle of IV drips.
💉 2. WTF Do They Even Do?
Sotac makes and sells pharma formulations across 15+ therapeutic areas:
🩺 Portfolio includes:
Anti-diabetics
Antibiotics (β-lactams + non-β-lactams)
Antihypertensives & cardiac drugs
Dermatology, antacids, analgesics
Antifungal, antiviral, iron supplements
Cephalosporins, anti-allergics
And vitamins/minerals for desi immunity boosts
Essentially, they don’t sell your cure — they make it for the big guys.
